Combined	combined	O	O	O	O
androgen	androgen	O	O	OTHERS	I
blockade-induced	blockade-induced	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
prostate	prostate	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
without	without	O	O	O	O
bone	bone	O	O	O	O
involvement	involvement	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
onset	onset	O	O	O	O
and	and	O	O	O	O
extent	extent	O	O	O	O
of	of	O	O	O	O
combined	combined	O	O	O	O
androgen	androgen	O	O	OTHERS	I
blockade	blockade	O	O	O	O
(CAB)-induced	(cab)-induced	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
prostate	prostate	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
without	without	O	O	O	O
bone	bone	O	O	O	O
involvement	involvement	O	O	O	O
.	.	O	O	O	O

PATIENTS	patients	O	O	O	O
AND	and	O	O	O	O
METHODS	methods	O	O	O	O
:	:	O	O	O	O
Forty-two	forty-two	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
biopsy-proven	biopsy-proven	O	O	O	O
prostatic	prostatic	O	O	OTHERS	I
adenocarcinoma	adenocarcinoma	O	O	OTHERS	I
[	[	O	O	O	O
26	26	O	O	O	O
with	with	O	O	O	O
stage	stage	O	O	O	O
C	c	O	O	OTHERS	I
(	(	O	O	O	O
T3N0M0	t3n0m0	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
16	16	O	O	O	O
with	with	O	O	O	O
stage	stage	O	O	O	O
D1	d1	O	O	O	O
(	(	O	O	O	O
T3N1M0	t3n1m0	O	O	O	O
)	)	O	O	O	O
]	]	O	O	O	O
were	were	O	O	O	O
included	included	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
patients	patients	O	O	O	O
received	received	O	O	O	O
CAB	cab	O	O	O	O
[	[	O	O	O	O
leuprolide	leuprolide	O	O	OTHERS	I
acetate	acetate	O	O	OTHERS	I
(	(	O	O	O	O
LHRH-A	lhrh-a	O	O	O	O
)	)	O	O	O	O
3.75	3.75	O	O	O	O
mg	mg	O	O	OTHERS	I
,	,	O	O	O	O
intramuscularly	intramuscularly	O	O	O	O
,	,	O	O	O	O
every	every	O	O	O	O
28	28	O	O	O	O
days	days	O	O	O	O
plus	plus	O	O	O	O
250	250	O	O	O	O
mg	mg	O	O	OTHERS	I
flutamide	flutamide	O	O	OTHERS	I
,	,	O	O	O	O
tid	tid	O	O	O	O
,	,	O	O	O	O
per	per	O	O	O	O
Os	os	O	O	O	O
]	]	O	O	O	O
and	and	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
for	for	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
by	by	O	O	O	O
physical	physical	O	O	O	O
examination	examination	O	O	O	O
and	and	O	O	O	O
laboratory	laboratory	O	O	O	O
tests	tests	O	O	O	O
at	at	O	O	O	O
baseline	baseline	O	O	O	O
and	and	O	O	O	O
4	4	O	O	O	O
subsequent	subsequent	O	O	O	O
intervals	intervals	O	O	O	O
(	(	O	O	O	O
1	1	O	O	O	O
,	,	O	O	O	O
2	2	O	O	O	O
,	,	O	O	O	O
3	3	O	O	O	O
and	and	O	O	O	O
6	6	O	O	O	O
months	months	O	O	O	O
post-CAB	post-cab	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Hb	hb	O	O	O	O
,	,	O	O	O	O
PSA	psa	O	O	O	O
and	and	O	O	O	O
Testosterone	testosterone	CHEMICALS	O	OTHERS	I
measurements	measurements	O	O	O	O
were	were	O	O	O	O
recorded	recorded	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
with	with	O	O	O	O
stage	stage	O	O	O	O
D2	d2	O	O	O	O
-	-	O	O	O	O
3	3	O	O	O	O
disease	disease	O	O	O	O
,	,	O	O	O	O
abnormal	abnormal	O	O	O	O
hemoglobin	hemoglobin	O	O	O	O
level	level	O	O	O	O
or	or	O	O	O	O
renal	renal	O	O	O	O
and	and	O	O	O	O
liver	liver	O	O	O	O
function	function	O	O	O	O
tests	tests	O	O	O	O
that	that	O	O	O	O
were	were	O	O	O	O
higher	higher	O	O	O	O
than	than	O	O	O	O
the	the	O	O	O	O
upper	upper	O	O	O	O
limits	limits	O	O	O	O
were	were	O	O	O	O
excluded	excluded	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
six	six	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
mean	mean	O	O	O	O
hemoglobin	hemoglobin	O	O	O	O
(	(	O	O	O	O
Hb	hb	O	O	O	O
)	)	O	O	O	O
levels	levels	O	O	O	O
were	were	O	O	O	O
significantly	significantly	O	O	O	O
declined	declined	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
from	from	O	O	O	O
baseline	baseline	O	O	O	O
of	of	O	O	O	O
14.2	14.2	O	O	O	O
g/dl	g/dl	O	O	O	O
to	to	O	O	O	O
14.0	14.0	O	O	O	O
g/dl	g/dl	O	O	O	O
,	,	O	O	O	O
13.5	13.5	O	O	O	O
g/dl	g/dl	O	O	O	O
,	,	O	O	O	O
13.2	13.2	O	O	O	O
g/dl	g/dl	O	O	O	O
and	and	O	O	O	O
12.7	12.7	O	O	O	O
g/dl	g/dl	O	O	O	O
at	at	O	O	O	O
1	1	O	O	O	O
,	,	O	O	O	O
2	2	O	O	O	O
,	,	O	O	O	O
3	3	O	O	O	O
and	and	O	O	O	O
6	6	O	O	O	O
months	months	O	O	O	O
post-CAB	post-cab	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

Severe	severe	O	O	O	O
and	and	O	O	O	O
clinically	clinically	O	O	O	O
evident	evident	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
of	of	O	O	O	O
Hb	hb	O	O	O	O
<	<	O	O	O	O
11	11	O	O	O	O
g/dl	g/dl	O	O	O	O
with	with	O	O	O	O
clinical	clinical	O	O	O	O
symptoms	symptoms	O	O	O	O
was	was	O	O	O	O
detected	detected	O	O	O	O
in	in	O	O	O	O
6	6	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
14.3	14.3	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
CAB-induced	cab-induced	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
normochromic	normochromic	O	O	O	O
and	and	O	O	O	O
normocytic	normocytic	O	O	O	O
.	.	O	O	O	O

At	at	O	O	O	O
six	six	O	O	O	O
months	months	O	O	O	O
post-CAB	post-cab	O	O	O	O
,	,	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
had	had	O	O	O	O
a	a	O	O	O	O
Hb	hb	O	O	O	O
mean	mean	O	O	O	O
value	value	O	O	O	O
of	of	O	O	O	O
10.2	10.2	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.1	0.1	O	O	O	O
g/dl	g/dl	O	O	O	O
(	(	O	O	O	O
X	x	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
SE	se	O	DISEASE	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
whereas	whereas	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
mild	mild	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
with	with	O	O	O	O
Hb	hb	O	O	O	O
mean	mean	O	O	O	O
value	value	O	O	O	O
of	of	O	O	O	O
13.2	13.2	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.17	0.17	O	O	O	O
(	(	O	O	O	O
X	x	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
SE	se	O	DISEASE	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
at	at	O	O	O	O
6	6	O	O	O	O
months	months	O	O	O	O
post-CAB	post-cab	O	O	O	O
was	was	O	O	O	O
predictable	predictable	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
reduction	reduction	O	O	O	O
of	of	O	O	O	O
Hb	hb	O	O	O	O
baseline	baseline	O	O	O	O
value	value	O	O	O	O
of	of	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
2.5	2.5	O	O	O	O
g/dl	g/dl	O	O	O	O
after	after	O	O	O	O
3	3	O	O	O	O
months	months	O	O	O	O
of	of	O	O	O	O
CAB	cab	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.01	0.01	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
CAB-induced	cab-induced	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
prostate	prostate	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
correlate	correlate	O	O	O	O
with	with	O	O	O	O
T	t	O	O	O	O
baseline	baseline	O	O	O	O
values	values	O	O	O	O
(	(	O	O	O	O
T	t	O	O	O	O
<	<	O	O	O	O
3	3	O	O	O	O
ng/ml	ng/ml	O	O	O	O
versus	versus	O	O	O	O
T	t	O	O	O	O
>	>	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
3	3	O	O	O	O
ng/ml	ng/ml	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
age	age	O	O	O	O
(	(	O	O	O	O
<	<	O	O	O	O
76	76	O	O	O	O
yrs	yrs	O	O	O	O
versus	versus	O	O	O	O
>	>	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
76	76	O	O	O	O
yrs	yrs	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
clinical	clinical	O	O	O	O
stage	stage	O	O	O	O
(	(	O	O	O	O
stage	stage	O	O	O	O
C	c	O	O	OTHERS	I
versus	versus	O	O	O	O
stage	stage	O	O	O	O
D1	d1	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Severe	severe	O	O	O	O
and	and	O	O	O	O
clinically	clinically	O	O	O	O
evident	evident	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
easily	easily	O	O	O	O
corrected	corrected	O	O	O	O
by	by	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
injections	injections	O	O	O	O
(	(	O	O	O	O
3	3	O	O	O	O
times/week	times/week	O	O	O	O
for	for	O	O	O	O
1	1	O	O	O	O
month	month	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
recombinant	recombinant	O	O	O	O
erythropoietin	erythropoietin	O	O	O	O
(	(	O	O	O	O
rHuEPO-beta	rhuepo-beta	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Our	our	O	O	O	O
data	data	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
rHuEPO-beta	rhuepo-beta	O	O	O	O
correctable	correctable	O	O	O	O
CAB-induced	cab-induced	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
occurs	occurs	O	O	O	O
in	in	O	O	O	O
14.3	14.3	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
prostate	prostate	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
after	after	O	O	O	O
6	6	O	O	O	O
months	months	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

